CD18 monoclonal antibody

Lymphotoxin β receptor (LTβR), also known as tumor necrosis factor receptor superfamily member 3 (TNFRSF3) and tumor necrosis factor receptor type III (TNF-RIII), is a type I membrane receptor expressed by stromal cells, including endothelial, mesenchymal, and epithelial cells, and by myeloid cells, such as dendritic cells and macrophages. When lymphotoxin α (LTα) is co-expressed with lymphotoxin β (LTβ) that possesses a transmembrane domain, it forms a cell surface-bound heterotrimer (LTα1β2) that exclusively binds to LTβR. The LTα1β2/LTβR pathway is required for the normal development of lymph nodes and Peyer’s patches. Disruption of the LTα1β2/LTβR pathway results in impaired protection from viral and bacterial infections . LTβR is also a receptor for LIGHT/TNFSF14. LTβR signaling through LIGHT/TNFSF14 regulates self-renewal and differentiation of hematopoietic and leukemic stem cells. In cancer cells, LTβR signaling via TRAF molecules promotes apoptosis. Agonistic antibodies to LTβR trigger cancer cell death and suppress tumor growth in vivo.

The monoclonal antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .